Skip to content
Screener

Royalty Pharma RPRX Cash collections from financial royalty assets

Cash collections from financial royalty assets at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$0
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$4.8M-1,140%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$4.8M-1,140%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.52M+24.2%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.52M+24.2%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$2.49M-10.7%

Other financials

Income statement

See full
Revenue$674.1M+16.5%
Operating income$133.1M-36.5%
Net income$17.9M-44.4%
EPS (diluted)$0.04-42.9%

Balance sheet

See full
Cash & equivalents$812.0M+28.5%
Total debt$9.0B+11.7%
Total equity$9.8B+3.1%
Total assets$19.8B+8.2%

Cash flow

See full
Operating cash flow$728.5M+100%

Valuation

See full
Market cap$25.38B+62.3%
Enterprise value$33.53B+45.6%
P/E31.1×+15.9×
P/S10×+3.2×

Profitability

See full
Operating margin59.6%-20.2pp
Net margin32.1%-12.3pp

Returns & leverage

See full
Return on equity8.5%-2.2pp
Debt / equity0.9×+0.1×
Current ratio2.8×+1.5×

Where this comes from

Reported directly by Royalty Pharma in its filing.

Tagged under the XBRL concept rprx:ProceedsFromCashCollectionsFromRoyaltiesReceivedOnFinancingReceivables.

The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:02 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001802768-26-000015
Line itemFor the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Cash flows from operating activities:
Cash collections from financial royalty assets$1,730,450$1,556,262
Cash collections from intangible royalty assets3,807417
Other royalty cash collections65,73355,810
Distributions from equity method investees24,73813,396
Interest received11,47420,687
Development-stage funding payments(123,351)(351,000)
Payments for operating and professional costs(73,040)(195,721)

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FAQ

What is Royalty Pharma's cash collections from financial royalty assets?
Royalty Pharma (RPRX) reported cash collections from financial royalty assets of $814.85M in Q2 2026.
How has Royalty Pharma's cash collections from financial royalty assets changed year-over-year?
Royalty Pharma's cash collections from financial royalty assets increased by 12.2% year-over-year, from $726.53M to $814.85M.
What is the long-term trend for Royalty Pharma's cash collections from financial royalty assets?
Over 4 years (2021 to 2025), Royalty Pharma's cash collections from financial royalty assets has grown at a 9.7% compound annual growth rate (CAGR), from $2.32B to $3.35B.
What does cash collections from financial royalty assets mean?
Cash collections from financial royalty assets as reported by Royalty Pharma plc Class A Ordinary Shares.

Ask your AI about Royalty Pharma's cash collections from financial royalty assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude